A second Phase 3 study of 18F-DCFPyL PET/CT Imaging in patients with biochemical recurrence of prostate cancer
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 09 May 2018 According to a Progenics Pharmaceuticals media release, company expects to initiate this trial by year end.
- 19 Mar 2018 New trial record
- 08 Mar 2018 According to a Progenics Pharmaceuticals media release, company expects to initiate this second Phase 3 study after completion of enrollment in OSPREY study which is expected in the second half of 2018.